聯環藥業(600513.SH)收到藥品GMP符合性檢查結果
格隆匯5月12日丨聯環藥業(600513.SH)公佈,近日,公司從江蘇省藥品監督管理局網站獲悉藥品GMP符合性檢查結果公吿(2021年第32號)。該次原料藥GMP符合性檢查是公司實施退城進園搬遷到新廠區新建生產線的相關檢查。
檢查範圍:原料藥[(鹽酸屈他維林、氨甲苯酸)(二車間C5廠房化工區和8號精烘包)、(蚓激酶)(二車間C5廠房化工區和9號精烘包)、(非洛地平)(一車間C2廠房化工區和3號精烘包)、(硫酸氫氯吡格雷)(一車間C2廠房化工區、C1廠房化工區和2號精烘包)、(醋酸地塞米松)(二車間C6廠房化工區和11號精烘包)]。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.